IQVIA (NYSE:IQV) Trading Down 4% – Time to Sell?

IQVIA Holdings Inc. (NYSE:IQV)’s share price was down 4% during mid-day trading on Thursday . The company traded as low as $214.01 and last traded at $218.0510. Approximately 856,203 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 1,799,256 shares. The stock had previously closed at $227.24.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Monday. Stifel Nicolaus lifted their target price on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. UBS Group increased their price target on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and increased their target price for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.44.

IQVIA Stock Down 2.1%

The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The stock’s 50 day simple moving average is $212.59 and its two-hundred day simple moving average is $185.57. The firm has a market cap of $37.89 billion, a P/E ratio of 30.52, a P/E/G ratio of 2.53 and a beta of 1.37.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same quarter last year, the company earned $2.84 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Boston Partners purchased a new position in IQVIA during the 3rd quarter worth approximately $676,698,000. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA in the second quarter worth approximately $515,772,000. Norges Bank purchased a new position in shares of IQVIA in the second quarter worth about $270,160,000. AQR Capital Management LLC grew its holdings in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.